Clinical Trials on Nasopharyngeal Carcinoma

Total 23248 results

Fudan University
Nanfang Hospital of Southern Medical University; Ningbo Medical Center Lihuili... and other collaborators

Recruiting

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Xinqiao Hospital of Chongqing
TCRCure Biopharma Ltd.

Recruiting

EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
First People's Hospital of Foshan

Not yet recruiting

Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms
Affiliated Cancer Hospital & Institute of Guangzhou...

Recruiting

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital
Zhejiang Cancer Hospital; Jiangxi Provincial Cancer Hospital

Not yet recruiting

Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

Nasopharyngeal Carcinoma

China
West China Hospital

Not yet recruiting

Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital
Zhejiang Cancer Hospital; Jiangxi Provincial Cancer Hospital

Not yet recruiting

Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Jiangsu Cancer Institute & Hospital

Not yet recruiting

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Chaosu Hu
Zhejiang Cancer Hospital; Fujian Cancer Hospital; Affiliated Hospital of Jiangnan... and other collaborators

Recruiting

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Guilin Medical University, China; First People's Hospital of Foshan

Recruiting

Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Wuzhou Red Cross Hospital; Hunan Cancer Hospital; Cancer Hospital of Guizhou... and other collaborators

Active, not recruiting

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Active, not recruiting

PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma (DIPPER)

Nasopharyngeal Neoplasms

China
Akeso
Akeso Tiancheng, Inc

Completed

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
University Health Network, Toronto

Active, not recruiting

Nasopharyngeal Carcinoma Post IMRT

Nasopharyngeal Carcinoma

Canada
Sue Yom
Bristol-Myers Squibb; National University Cancer Institute, Singapore

Active, not recruiting

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

United States, Singapore
Zhongshan People's Hospital, Guangdong, China

Active, not recruiting

Nasopharyngeal Carcinoma Screening in Zhongshan City

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chang Gung Memorial Hospital

Completed

PET and MRI in Prognosis Prediction of NPC

Nasopharyngeal Carcinoma

Taiwan
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Completed

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (CONTINUUM)

Nasopharyngeal Neoplasms

China
Affiliated Cancer Hospital & Institute of Guangzhou...

Completed

Nedaplatin in Treatment for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fudan University

Completed

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
First Affiliated Hospital of Guangxi Medical University

Completed

Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Massachusetts General Hospital
Dana-Farber Cancer Institute; Brigham and Women's Hospital

Completed

Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

United States
Sun Yat-sen University

Withdrawn

Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Guilin Medical University, China; First People's Hospital of Foshan

Unknown

Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The University of Hong Kong

Unknown

Serial Plasma EBV DNA for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Hong Kong
Sun Yat-sen University

Unknown

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Chaosu Hu

Unknown

De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Completed

Prospective Comparisons of Clinical Trial and Real-world Outcomes in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hong Kong Nasopharyngeal Cancer Study Group Limited
The Hong Kong Anti-Cancer Society; hong Kong Cancer Fund

Completed

Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
National University Hospital, Singapore

Completed

Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

Singapore
Fudan University

Unknown

Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Completed

Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT

Nasopharyngeal Carcinoma

China
Guiyang Medical University

Unknown

By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC

Nasopharyngeal Carcinoma

China
China Medical University Hospital

Unknown

To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Taiwan
Wei Jiang
Wuzhou Red Cross Hospital; Guangxi Naxishan Hospital; LiuZhou People's Hospital; Guigang People's Hospital and other collaborators

Unknown

Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Nanfang Hospital of Southern Medical University

Unknown

IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Sun Yat-sen University

Active, not recruiting

Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Unknown

Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Completed

Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Changjie Huang

Unknown

The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Jiangsu Cancer Institute & Hospital

Terminated

NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation

Nasopharyngeal Carcinoma

China
National Health Research Institutes, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Completed

A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Taiwan
Cancer Hospital of Guangxi Medical University

Unknown

Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Jiangsu Cancer Institute & Hospital

Completed

Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Unknown

Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC (NPC)

Nasopharyngeal Carcinoma

China

Clinical Trials on Nasopharyngeal Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations